1. Home
  2. FRSX vs LABT Comparison

FRSX vs LABT Comparison

Compare FRSX & LABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Foresight Autonomous Holdings Ltd.

FRSX

Foresight Autonomous Holdings Ltd.

N/A

Current Price

$1.15

Market Cap

5.0M

Sector

Technology

ML Signal

N/A

Logo Lakewood-Amedex Biotherapeutics Inc. Common Stock

LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

N/A

Current Price

$2.38

Market Cap

5.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FRSX
LABT
Founded
N/A
N/A
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0M
5.3M
IPO Year
2016
2026

Fundamental Metrics

Financial Performance
Metric
FRSX
LABT
Price
$1.15
$2.38
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
32.8K
234.5K
Earning Date
05-15-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.78
$1.66
52 Week High
$3.00
$6.85

Technical Indicators

Market Signals
Indicator
FRSX
LABT
Relative Strength Index (RSI) 43.54 50.04
Support Level $1.11 $1.89
Resistance Level $1.47 $2.44
Average True Range (ATR) 0.10 0.33
MACD 0.01 -0.01
Stochastic Oscillator 43.48 38.71

Price Performance

Historical Comparison
FRSX
LABT

About FRSX Foresight Autonomous Holdings Ltd.

Foresight Autonomous Holdings Ltd is a technology company engaged in the development of 3D perception systems and cellular-based applications. The company designs, develops, and commercializes in-line-of-sight vision systems and beyond-line-of-sight accident prevention solutions through its subsidiaries. Its solutions are based on stereo vision, 3D perception, and V2X technologies, aimed at improving safety by enabling accurate obstacle detection and real-time alerts. The company targets multiple industries, including automotive, defense, agriculture, and heavy equipment.

About LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock

Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.

Share on Social Networks: